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Prostate cancer is particularly suited for active immunotherapy because of the expression
of a distinctive number of antigens which are overexpressed on prostate cancer cells and
cell lines.There is evidence in this disease that tumors promote immune tolerance starting
early in the disease course. As such, chemotherapy, by suppressing tumors and activat-
ing immune system homeostatic mechanisms, may help overcome this tumor-induced
immune tolerance. Sipuleucel-T which has recently been approved in the US, is an autolo-
gous cellular product immunotherapy that induces immune activity likely through activation
of dendritic cells. This was associated with a survival beneﬁt in the absence of signiﬁcant
toxicity. However, a post hoc analysis of phase III trial participants found a substantial
survival beneﬁt to receiving docetaxel some months after sipuleucel-T. However, another
phase III immunotherapy trial combining a prostate cancer therapeutic vaccine GVAX plus
docetaxel versus standard docetaxel therapy in advanced prostate cancer, observed a
lower overall survival with the vaccine regimen. These trials highlight major unresolved
questions concerning the optimum choice, dosing, and timing of chemotherapy relative
to active immunotherapy and the overall merits of considering this approach. The ideal
treatment approach remains unclear; advances in biomarker validation and trial design may
likely improve our ability to assess biologic beneﬁt irrespective of the development of true
antitumor immunity.
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INTRODUCTION
Therapeutic options for the treatment of castration-resistant
prostate cancer (CRPC) have dramatically improved with the
approval of three new treatments each of which is unique in its
ability to target a particular mechanism within the spectrum of
prostate cancer growth.While docetaxel remains theﬁrst-line stan-
dard of care for metastatic CRPC due to its demonstrated survival
beneﬁt, improved pain control and quality of life, cabazitaxel, a
semi-synthetic derivative of the 10-deacetylbaccatin III that pro-
motes tubulin assembly in vitro and stabilizesmicrotubules against
cold-induced depolymerization, salvaged docetaxel failures with
beneﬁt of antitumor effects and a small survival advantage. Abi-
raterone (Zytiga™), an inhibitor of CYP-17, recently received FDA
approval as another post-docetaxel second-line agent, and as seen
with cabazitaxel (Jevtana™), these agents offered about a 4-month
survival beneﬁt, respectively. For the ﬁrst time, immunotherapy,
a long-sought after treatment approach that has been fraught
with suboptimal results has ﬁnally come of age in the form of
active cellular product, Sipuleucel-T, also associated with a sur-
vival beneﬁt. While there are data to suggest that the ﬁrst two
treatments arewell-placed in the post-docetaxel setting, their entry
into earlier clinical states of prostate cancer growth is being inves-
tigated. Sipuleucel-T remains for castration-resistant disease at
any stage.
The rationale for immunotherapy in prostate cancer has been
based on several observations. First, there are a several altered self-
antigens, glycoproteins, and glycolipids, which are overexpressed
or underglycosylated on prostate cancer cells and cell lines (Slovin,
2008). These include the mucins MUC-1, 2, Globo H, GM-2,
prostate stem cell antigen (PSCA), prostate speciﬁc antigen (PSA),
and prostate speciﬁc membrane antigen (PSMA). PSMA has been
a target for a variety of approaches including protein and peptide
vaccines, naked DNA vaccines, chemotherapy-anti-PSMA mon-
oclonal antibody conjugates, as well as radiolabeled anti-PSMA
monoclonal antibodies. Second, a biomarker PSA, can be used to
monitor disease activity and/or progression. Third,prostate cancer
can have a long natural history, thus all clinical states can be poten-
tially amenable to treatment and therefore, immunotherapy can
be a rational approach for patients with variable disease burdens.
Last, there are other biomarkers which may more accurately reﬂect
the true biologic response to treatment. These include circulating
tumor cells (CTCs), as well as markers of bone turnover.
Despite the attempt of many vaccines to break immunologic
tolerance, the overall failure to demonstrate clinical beneﬁt despite
induction of antibodies against the immunogen has remained a
clinical challenge. Another issue has been the lack of immedi-
acy of detecting clinical beneﬁt; several recent trials in metasta-
tic melanoma using a monoclonal antibody against checkpoint
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inhibitor CTLA-4 demonstrated an antitumor effect preceded ini-
tially by tumor growth then a remission. There still remains the
unanswered question as to which clinical state would likely derive
the best beneﬁt from vaccines: the state of biochemical relapse
where logically one is targeting micrometastatic disease or, non-
castrate and castrate metastatic disease where one can actually
follow the radiographic response to treatment. Where to position
these new agents in the clinical state scheme continues to be a
treatment challenge as more patients will likely be on these estab-
lished agents earlier in the disease state while remaining stable for
longer periods of time.
Sipuleucel-T is a cellular immunotherapy product that consists
of an enrichedpopulation of a patient’s peripheral bloodmononu-
clear cells (PBMCs), which were exposed in vitro to a fusion
protein comprised of granulocyte/macrophage-colony stimulat-
ing factor (GM-CSF) andprostatic acid phosphatase (PAP;Kantoff
et al., 2010). These PMBCs, which include a large proportion
of antigen-presenting cells, are infused back into the patient to
stimulate antitumor T-cell responses (Kantoff et al., 2010). The
speciﬁc indication of sipuleucel-T includes asymptomatic or min-
imally symptomatic, non-visceral, metastatic prostate cancer in
the pre-docetaxel space.
Three phase III sipuleucel-T trials enrolled CRPC patients with
only minor symptoms or functional impairment, and no current
chemotherapy; however, 5.5, 10.2, and 18.2% of patients had prior
chemotherapy (Higano et al., 2009; Kantoff et al., 2010). The trials
reported an increase of 4.1–4.3months in median overall survival
compared with placebo. Estimated survival at 36months was 32–
33% in the active arms versus 15–23% in the placebo arms (Higano
et al., 2009; Kantoff et al., 2010). However, early results of com-
bination therapy with docetaxel have not demonstrated beneﬁts
of sipuleucel-T use following chemotherapy (Higano et al., 2009;
Kantoff et al., 2010). These two analyses focused on the treatment
beneﬁt derived from the administration of sipuleucel-T with or
without subsequent docetaxel. In the ﬁrst two phase III trials, 32%
of the participants received docetaxel after either sipuleucel-T or a
similar product prepared from their frozen cells (which was given
to crossover placebo recipients after disease progression; Petrylak
et al., 2007; Higano et al., 2009; Petrylak, 2011).
An exploratory post hoc analysis of docetaxel with or with-
out early sipuleucel-T found that there was a beneﬁt to receiving
docetaxel some months after sipuleucel-T. Median survival was
34.5months for patients who received sipuleucel-T followed later
by docetaxel (N = 51); 25.7months for crossover placebo recip-
ients who also received docetaxel (N = 21); and 20.2months for
placebo patients who received docetaxel without ever receiving
a vaccine product (N = 10). The adjusted survival hazard ratio
(HR) for the ﬁrst of these groups compared with the others was
2.53 (P = 0.006; Petrylak et al., 2007; Petrylak, 2011).
RATIONALE FOR COMBINING CHEMO- AND
IMMUNOTHERAPIES
DO COMBOS ENHANCE EFFICACY VIA IMMUNOLOGIC MODULATION
OR VIA TRUE BIOLOGIC (ANTITUMOR) EFFECT?
Although an attractive idea, chemotherapy-vaccine combinations
have not been widely applied. Much of the chemotherapy/vaccine
combination data are from preclinical and murine studies, or are
based on small phase I trials. In mouse models of colon and breast
cancer, paclitaxel, docetaxel, or cisplatin subsequent to vaccina-
tion enhanced the effectiveness of the vaccine-generated cytotoxic
lymphocytes (CTLs), probably by causing an increase in tumor
cell permeability to granzyme B (Ramakrishnan et al., 2010). Cell
death in the vaccinated and treated mouse cancer models included
a desirable bystander effect in which the vaccine-induced CTLs
caused apoptosis in neighboring tumor cells not expressing the
vaccine antigens.
While the docetaxel used after early sipuleucel-T was an
exploratory study with small numbers, the results, while incon-
clusive, suggest that the potential to impact on disease with com-
bination therapy is feasible. A number of authors have noted
that natural cell-mediated immune responses (i.e., tumor inﬁl-
tration by IFNγ-producing CD4+ and CD8+ cells) correlate with
improved survival in a variety of cancers (Pagès et al., 2008; Mlec-
nik et al., 2011; Vesely et al., 2011) and some reports have even
suggested that the type and density of inﬁltrating lymphocytes
are more predictive of disease progression than traditional tumor
staging (Pagès et al., 2008; Mlecnik et al., 2011).
However, it is felt that the chronic inﬂammatory milieu
that develops during tumor growth compromises the immune
response while promoting further progression of the malignancy
(Wu and Zhou, 2009; Grivennikov et al., 2010; Vesely et al., 2011).
Chronic inﬂammation causes immune cells to release cytokines
such as TNF-α, TGF-β, and IL-6, which recruit myeloid-derived
suppressor cells (MDSC) and directly reduce immune cell activ-
ity. These cytokines also promote metastatic transition later in the
disease process.
In addition, tumor cells evade CTLs through a number of
strategies, including blocking antigen presentation, loss of MHC,
and apoptosis (Poschke et al., 2011; Vesely et al., 2011). They can
also produce immunosuppressive cytokines such as TGF-β and
VEGF. These cytokines directly reduce CTL numbers and recruit
CD25+ Treg cells and MDSC that repress the immune response.
Yet anothermechanism employed by tumor cellsmay cause reduc-
tion in CTL numbers by expressing certain receptor ligands (e.g.,
PD-L1 and FasL).
There is considerable evidence in prostate cancer that tumors
promote immune tolerance starting early in the disease (Diener
et al., 2009; Drake, 2010). In a transgenic mouse model of prostate
cancer, CD8+ and CD4+ cells speciﬁc to prostate antigens inﬁl-
trate prostate tumors but are anergic or non-functional. The
encounterwith tumor antigens apparently shiftsCD4+ andCD8+
cells toward a suppressive (Treg) phenotype. Patient biopsies show
that prostate tumor inﬁltrating CD4+ cells include high levels of
Treg cells (Sfanos et al., 2008).Humanprostate tumors also contain
elevated populations of possibly protective Th17 cells populations,
but only in early disease (low-grade tumors; Sfanos et al., 2008).
IS THERE A LINK BETWEEN ANTI-CANCER IMMUNITY AND RESPONSE
TO CHEMOTHERAPY?
Chemotherapy is widely held to be immunosuppressive, but in
fact, it has immunomodulatory effects (Zitvogel et al., 2008; Ma
et al., 2011). Merely debulking the tumors reverses tumor-induced
immune tolerance, possibly through reducing the amount of sup-
pressive cytokines secreted by malignant cells (Zitvogel et al.,
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2008). In addition, the transient lymphopenia caused by properly
dosed chemotherapy activates homeostatic mechanisms, elim-
inating excess suppressor cells, and stimulating tumor-speciﬁc
effector T-cell proliferation as well as dendritic cell maturation
(McDonnell et al., 2011).
Some chemotherapeutic agents promote speciﬁc immune cell
types. For example, docetaxel administration in a mouse model
selectively decreased MDSCs while increasing CTL responses
(Kodumudi et al., 2010). Docetaxel may have a relatively potent
effect, but other taxanes also alter cytokine patterns and enhance
lymphocyte proliferation, as well as the cytotoxic activity of NK
and LAK cells, while reducing Treg cell populations (Javeed et al.,
2009; Vicari et al., 2009).
Another murine study immunized mice with implanted colon
tumors expressing human carcinoembryonic antigen (CEA). The
experimental vaccine was based on a poxvirus vaccine contain-
ing genes for CEA and costimulatory molecules (CEA-TRICOM;
Garnett et al., 2008). Administering a standard dose of doc-
etaxel 4 days after 2 poxvirus immunizations improved vaccine-
speciﬁc immune responses. It also induced antigen-speciﬁc T-cell
responses to tumor-derived antigens distinct from the antigen
used in the vaccine (the “antigen cascade” or “epitope spreading”
possibly due to the release of antigens from dying cells). Doc-
etaxel was effective only when administered after immunization.
If administered beforehand, docetaxel inhibited cellular infection
by the viral vaccine or antigen expression in the cells that did
become infected (Garnett et al., 2008).
The optimal dosing of chemotherapy combined with vaccines
remains unclear. A study that investigated daily low-dose pacli-
taxel found that by targeting HPV E7+ implanted tumors in mice
receiving aDNAvaccine, survival was extended and tumor growth,
delayed. The results were improved when compared with the vac-
cine alone, the vaccine plus high-dose paclitaxel, or high-dose,
twice-weekly paclitaxel alone (Chen et al., 2010). Daily low-dose
paclitaxel did not result in the signiﬁcant T-cell declines induced
by high-dose paclitaxel. When administered with the vaccine,
daily low-dose paclitaxel resulted in a higher CD8+ T-cell/Treg
ratio than either the vaccine alone or the vaccine plus high-
dose paclitaxel. Furthermore, the low-dose chemotherapy had
greater anti-angiogenic effects than did high-dose (Chen et al.,
2010).
Low-dose cyclophosphamide also has well-documented mod-
ulatory effects (Sistigu et al., 2011). It reduces the Treg population,
inhibits the activity of the remaining Treg cells, and stimulates
cell-mediated immunity (Garnett et al., 2008). The drug is now
reappearing in vaccine trials after a hiatus of many years. In
a transgenic murine prostate cancer model, administering low-
dose cyclophosphamide 1–2 days before immunization with a
whole-cell,GM-CSF-secreting vaccine (GVAX) resulted in a tumor
shrinkage effect not observed with the vaccine alone (Wada et al.,
2009). This effect seemed related to a reduced Treg population
in the tumor and its draining lymph node as well as increased
dendritic cell activation (Wada et al., 2009).
Other studies have found speciﬁc beneﬁts from high-dose but
submyeloablative chemotherapy. An adenovirus-based vaccine
was found to have limited effectiveness in mice with established
melanoma tumors unless the mice were pretreated with higher
doses of cyclophosphamide (Grinshtein et al., 2009). The com-
bination resulted in tumor regression due to the high frequency
of vaccine antigen-speciﬁc T cells, reﬂecting cyclophosphamide’s
general promotion of cell-mediated immunity. Another approach
used cisplatin/vinorelbine to induce leukopenia as well as down-
modulated reconstitution of Treg cells when compared with effec-
tor T cells. Gameiro et al. (2011) and Noguchi et al. (2004, 2011),
have presented their experience of using low-dose estramustine
phosphate (initially administered as 280mg daily in concert with a
personalized peptide vaccine in HLA-A2+ or -A24+patients with
CRPC (Noguchi et al., 2004). Other than good tolerability and
feasibility of administration, there were no preclinical studies to
suggest that this drug had a direct immunomodulatory effect.Nev-
ertheless, 10 of 11 patients who received a combination of peptide
vaccination and estramustine showed a serum PSA decrease; 8
patients showed a PSA decrease of ≥50%. One of two patients
with measureable disease showed a 44% decrease in lymph node
metastasis; no changes were seen in patients with bone lesions.
Estramustine-induced immunosuppression was analyzed in 10
of 11 patients by IFN-γ productions to PHA, EBV peptide and
the vaccinated peptides. Immunologic responses were observed;
no signiﬁcant immune suppression was seen when the peptide
was given along with a smaller dose of estramustine (Noguchi
et al., 2004). These responses were thought to be mediated by rest-
ing T cell, memory T cells, and a combination of memory and
activated T cells, respectively (Noguchi et al., 2004). These obser-
vations were further extended into another phase I multicenter
study (Noguchi et al., 2011) of 15 patients treated with los dose
estramustine and ITK-1, a peptide set consisting of 14 kinds of
peptide which induced HLA-A24-resetricted tumor-speciﬁc cyto-
toxic activity. Patient were treated with the top four peptides
shown to be immunogenic based on pre-vaccination measure-
ment of peptide-speciﬁc IgG in plasma reactive to ITK-1. While
safe, in vitro analysis did not reveal any correlation between the
peptide dose and the generation of speciﬁc T cells from vacci-
nated patients. A median survival of 23.8months was reported
with this combination regimen albeit the exact immune mech-
anism (Noguchi et al., 2011), if any, which contributed to this
remains unclear.
CAN REDUCING OR SUPPRESSING THE REGULATORY T-CELL
POPULATION WITH NON-CHEMOTHERAPEUTIC AGENTS ENHANCE THE
RESPONSE TO VACCINE?
Improving vaccine response by inactivating Treg cells has been
attempted through speciﬁc targeting of the T-cell checkpoint
inhibitor, CTLA-4 with a monoclonal antibody such as ipili-
mumab (Noguchi et al., 2004, 2011; Saha and Chatterjee, 2010).
Preliminary clinical trials suggest that administering a therapeu-
tic vaccine followed by ipilimumab enhances immune responses
and tumor reduction in prostate and ovarian cancers as well as
melanoma (Chakraborty et al., 2007; Li et al., 2007; Gerritsen
et al., 2008; Mohebtash et al., 2009). In a non-comparative phase
I trial (N = 30) of ipilimumab plus the PSA-TRICOM vaccine
in prostate cancer, overall survival was 31.8months compared
with an expected survival of 18.5months based on baseline fac-
tors (Halabi nomogram-predicted survival,HPS;Hodi et al., 2008;
Yuan et al., 2008).
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Several studies in melanoma have not found additional beneﬁt
for therapeutic vaccines beyond that of ipilimumab alone (Halabi
et al., 2003; Madan et al., 2010a). In both the prostate cancer and
melanoma studies, the vaccines were administered simultaneously
with the course of ipilimumab; there was no attempt to evalu-
ate sequential therapy (Halabi et al., 2003; Madan et al., 2010a).
Furthermore, the melanoma studies associated ipilimumab with
autoimmune events such as diarrhea, hypophysitis, transamini-
tis, and rash, as did a prostate cancer study of ipilimumab alone
after radiotherapy (Mohebtash et al., 2009; Sarnaik et al., 2011).
The severity of the adverse events appeared to be related to the
level of response to ipilimumab. Overall, the results suggest that
chemotherapy, albeit at less than therapeutic doses, may induce
a wide range of immune effects which may ultimately lead to a
systemic antitumor effect, albeit several weeks to months after
treatment. Another checkpoint inhibitor, programmed death 1
(PD-1),PD-1 is amemberof the extendedCD28/CTLA-4 family of
T-cell regulators. Monoclonal antibodies to PD-1 are currently in
clinical trials and have shownpromise in renal cell carcinoma, lung
cancer, and melanoma. Combinatorial trials with anti-CTLA-4
and other immune modulatory agents are currently ongoing.
In a hypothesis-driven pilot study based on a preclinical tumor-
bearing model of mice immunized with peptide pulse dendritic
cells followed by an anti-VEGF antibody, patients with biochem-
ically relapsed prostate cancer were treated with three doses of
Sipuleucel-T followedby every 2week infusionswithBevacizumab
at 10mg/kg (Rini et al., 2006). The preclinical data suggested a
more robust and durable antitumor immune response in those
mice treated with dendritic cells and Bevacizumab compared with
peptide-pulsed DC alone. Several patients had modulation of
PSA and immunologic monitoring suggested brisk T-cell prolif-
eration which was associated with a >50% PSA decline in one
patient. All patients had increased production of interferon-γ by
EliSPOT assay (Rini et al., 2006). Though a very small patient
cohort was studied, this work opened a new perspective, intro-
ducing the possibility of using biologic agents such as VEGF
inhibitors or even cytokines in combinatorial approaches with
immunotherapy.
CAN COMBINATION TRIALS DEMONSTRATE AN IMPACT ON TUMOR
RESPONSE OR OVERALL SURVIVAL IN PROSTATE CANCER?
Recent attempts to demonstrate improvement in overall or
progression-free survival (PFS) have been shownusing a poxvirus-
PSA recombinant vaccine, a mixture of recombinant pox viruses
expressing either PSA or the B7.1 costimulatory molecule
(Gameiro et al., 2011).A vaccinia-based vaccine is usually adminis-
tered once followed by monthly injections of fowlpox-PSA recom-
binant virus in a primeboost strategy. Each vaccination is adminis-
teredwithGM-CSF (Arlen et al., 2006). In a phase II study,patients
withmetastaticCRPC(N = 28) received thepoxvirus-PSAvaccine
2 weeks apart for the ﬁrst month and then monthly until disease
progression occurred. Half the group additionally received doc-
etaxel/dexamethasone therapy in 3-weeks-on/1-week-off cycles
(Arlen et al., 2006). Eleven patients (78.6%) in the vaccine-alone
arm were changed to docetaxel upon evidence of progression.
Median time to progression was 1.8months in the vaccine-alone
arm and 3.2months in the vaccine plus docetaxel arm. Notably,
patients experienced a median 6.1-month progression-free period
after progressing on the vaccine alone and then switching to doc-
etaxel. PFS was 3.7months in an historic control group receiving
docetaxel alone (Arlen et al., 2006). All evaluable vaccine recip-
ients exhibited increased PSA-speciﬁc T cells (median 3.33-fold
increase in both arms). In the three vaccine-alone recipients who
were examined, T-cell responses emerged, as well as responses to
other prostate tumor antigens (PAP, PSMA, and/or MUC-1). This
may have been due to an epitope-spreading phenomenon pur-
suant to the tumor cell death by the vaccine-induced PSA-speciﬁc
T-cell response (Arlen et al., 2006).
ProstVac VF (PSA-TRICOM) is a second-generation vaccine
employing recombinant vaccinia- and fowlpox-expressing PSA
plus 3 T-cell costimulatory molecules, LFA-3, B7.1, and ICAM-1
(Poschke et al., 2011). It elicits a more robust antitumor response
than the original poxvirus-PSA immunization (Poschke et al.,
2011). An ongoing randomized double-blind placebo-controlled,
multicenter phase III efﬁcacy trial of PROSTVAC in men with
asymptomatic or minimally symptomatic, CMPC is a 3-arm
study and will evaluate overall survival in two separate com-
parisons, PROSTVAC plus adjuvant dose GM-CSF versus con-
trols, and PROSTVAC without GM-CSF versus controls: (1) (Arm
V+G) PROSTVAC-V/F plus adjuvant dose GM-CSF; (2) (Arm
V) PROSTVAC-V/F plus GM-CSF placebo; (3) (Arm P) Double
placebo (vector placebo plus GM-CSF placebo).
Prostate GVAX is a polyvalent vaccine comprised of irradiated
whole cells from two prostate cancer cell lines, the androgen-
dependent LNCaP and the androgen-refractory PC3, respectively
(Drake, 2010). In this vaccine, the cells are transduced with a
gene for GM-CSF in order to improve their immune-stimulatory
effects (Drake, 2010). Phase II studies showed promising responses
and led to two phase III studies that included docetaxel. The
phase III VITAL-1 trial directly compared GVAX (biweekly for
the ﬁrst 26 weeks, then monthly) with standard tri-weekly doc-
etaxel plus prednisone (Higano et al., 2009). The study population
included chemotherapy-naïve men with CPRC and negligible
pain. This trial was terminated early due to futility: there was
little chance of reaching the primary endpoint, improved survival,
even though indications of the vaccine efﬁcacy were observed.
Median survival was 20.7months on GVAX and 21.7months
on docetaxel/prednisone (P = 0.78). Of note, grade 3/4 adverse
events were considerably less frequent with GVAX (8.8% of GVAX
recipients vs 43% of those on docetaxel; Higano et al., 2009).
The futility analysis took on particular importance because
of the results in the other phase III GVAX trial (VITAL-2).
That study administered docetaxel every 3 weeks followed 2 days
later by GVAX immunization. After 10 docetaxel cycles, GVAX
every 4 weeks was administered alone as maintenance therapy.
The comparator group received standard docetaxel/prednisone
for 10 cycles (Small et al., 2009). The study had a planned
enrollment of 600 taxane-naïve patients with metastatic CRPC
requiring opioid pain management; overall survival was the pri-
mary endpoint (Small et al., 2009). However, the trial (N = 408
actual enrollment) was halted prematurely due to an excess of
deaths in the GVAX arm (67 vs 47). Median overall survival
was 12.2months in the GVAX/docetaxel arm and 14.1months
in the docetaxel/prednisone arms (HR= 1.70; 95% CI, 1.15–2.53,
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P = 0.0076). The investigators were unable to identify safety issues
or other reasons for the excess deaths.
It should be noted that no phase II trials were conducted prior
to VITAL-2 in order to test various docetaxel/GVAX doses and
sequences. Judging by the VITAL-1 results with GVAX alone, it is
conceivable that the concurrent high-dose docetaxel undercut the
GVAX effect. Administering GVAX before or after docetaxel rather
than concurrently might yield a more successful result. Another
possibility is that some of the study population had disease that
was too advanced to beneﬁt from the vaccine.
CONCLUSION: HOW SHOULD INVESTIGATORS GO FORWARD WITH
IMMUNOTHERAPY TRIALS?
There remain at least three questions which remain unaddressed
with respect to chemotherapy administered with an immunother-
apy: (1) what will be the most effective chemotherapy, (2) what
is the most appropriate to foster synergism, and (3) what is
the sequence of reagent delivery to foster maximum beneﬁt?
Chemotherapies with potential for beneﬁt include the taxanes,
anthracyclines, and cyclophosphamide but it remains unclear
whether newer targeting agents against the androgen receptor
(AR), or signaling pathwaysmay also play a role. All of these agents
appear to have positive immunomodulation in and of themselves
that might enhance the response to a therapeutic vaccine. As
discussed earlier, chemotherapy given in lower-than-therapeutic
doses may be favored, as those may selectively alter cell popu-
lations and inhibit angiogenesis (Chen et al., 2010; Emmeneg-
ger et al., 2011; Sistigu et al., 2011). Higher doses may permit
greater immune activity and more immunogenicity due to tumor
debulking and cell death (Ma et al., 2011). Lower doses and/or
abbreviated courses would be less toxic overall, and also less
immunosuppressive. They would also allow frequent, even daily,
dosing (metronomic administration) for a steady effect over time.
Sequencing of chemotherapy, as in dosing, depends on the
agent’s mechanism of action. Initiation of chemotherapy prior to
vaccinationwould be an option if the goal was to reset the immune
system by reducing the level of suppressive cells. Conversely, ini-
tiation of chemotherapy during or after vaccination would be an
option if the strategy was to impede the tumor and potentiate or
broaden the vaccine-induced responses.
The question of which patient, disease stage, and treatment
history is most appropriate for therapeutic vaccine schemes also
arises. Late-stage patients may have had their immune systems
compromised by extensive chemotherapy and the evolving tumor
escape strategies (Higano et al., 2009). One implication is that the
patients with shorter life expectancies will not beneﬁt from vac-
cine therapy; for example, as demonstrated in the GVAX/docetaxel
combination results (Beer et al., 2008). Considering the safety of
vaccines relative to standard chemotherapy, clinical trials could
justify enrolling patients in earlier stages of disease in lieu of
conventional chemotherapy alone.
CAN VACCINE TRIAL ENDPOINTS BE IMPROVED?
Another reason for suboptimal results with vaccines in popula-
tions with advanced disease and low life expectancies is that the
timeframe needed to observe a clinical response may be delayed.
Researchers have realized that responses to immunotherapies are
slower compared to chemotherapy (Wolchok et al., 2009; Hoos
et al., 2010; Madan et al., 2010b; Emmenegger et al., 2011). The
disease could remain stable or even progress for some months
before protective immune responses are apparent. Alternatively,
the initial vaccine-induced inﬂammatory ﬂare may be mistaken
for tumor growth.Various groups have therefore proposed revised
endpoints for cancer vaccine trials that place greater emphasis
on overall survival or long-term disease stability rather than PFS.
The emphasis is on minimizing premature discontinuation, and
allowing patients to continue with therapy despite early, minor
progression (Hoos et al., 2010; Emmenegger et al., 2011).
These endpoints may be more appropriate, but they unfortu-
nately codify the extension of vaccine/chemotherapy combina-
tion studies’ length and complexity. This further compromises
an area that historically has been of low research priority. Bio-
markers of immune response that reliably predict treatment
outcome would simplify researchers issues, allowing for more
rapid identiﬁcation and the optimization of effective regimens
before trials have reached clinical endpoints (Hoos et al., 2007;
Disis, 2011; Emmenegger et al., 2011). These would ideally give
advance indication of clinical beneﬁt without the long follow-
up required to observe clinical endpoints. In general, biomarkers,
there remains the question as to whether blood biomarkers reﬂect
conditions within the tumor itself of within the surrounding
milieu. There is also a need to standardize immune assays so
that study results become more easily reproducible (Hoos et al.,
2010).
REFERENCES
Arlen, P. M., Gulley, J. L., Parker, C.,
Skarupa, L., Pazdur, M., Panicali, D.,
Beetham, P., Tsang, K. Y., Grosen-
bach, D. W., Feldman, J., Stein-
berg, S. M., Jones, E., Chen, C.,
Marte, J., Schlom, J., and Dahut,
W. (2006). A randomized phase
II study of concurrent docetaxel
plus vaccine versus vaccine alone
inmetastatic androgen-independent
prostate cancer. Clin. Cancer Res. 12,
1260–1269.
Beer, T. M., Slovin, S. F., Higano, C.
S., Tejwani, S., Dorff, T. B., Stanke-
vich, E., Lowy, I., and Prostate
Cancer Clinical Trials Consortium.
(2008). Phase I trial of ipilimumab
(IPI) alone and in combination
with radiotherapy (XRT) in patients
with metastatic castration resistant
prostate cancer (mCRPC). J. Clin.
Oncol. 26, abstr. 5004.
Chakraborty,M., Schlom, J., andHodge,
J. W. (2007). The combined activa-
tion of positive costimulatory sig-
nals with modulation of a neg-
ative costimulatory signal for the
enhancement of vaccine-mediated
T-cell responses. Cancer Immunol.
Immunother. 56, 1471–1484.
Chen, C. A., Ho, C. M., Chang, M. C.,
Sun, W. Z., Chen, Y. L., Chiang, Y.
C., Syu, M. H., Hsieh, C. Y., and
Cheng, W. F. (2010). Metronomic
chemotherapy enhances antitumor
effects of cancer vaccine by deplet-
ing regulatory T lymphocytes and
inhibiting tumor angiogenesis. Mol.
Ther. 18, 1233–1243.
Diener, K. R., Woods, A. E., Man-
avis, J., Brown, M. P., and Hayball,
J. D. (2009). Transforming growth
factor-beta-mediated signaling in T
lymphocytes impacts on prostate-
speciﬁc immunity and early prostate
tumor progression. Lab. Invest. 89,
142–151.
Disis, M. L. (2011). Immunologic bio-
markers as correlates of clinical
response to cancer immunotherapy.
Cancer Immunol. Immunother. 60,
433–442.
Drake, C. G. (2010). Prostate cancer as a
model for tumour immunotherapy.
Nat. Rev. Immunol. 10, 580–593.
Emmenegger, U., Francia, G., Chow,
A., Shaked, Y., Kouri, A., Man,
S., and Kerbel, R. S. (2011).
Tumors that acquire resistance to
low-dose metronomic cyclophos-
phamide retain sensitivity to max-
imum tolerated dose cyclophos-
phamide. Neoplasia 13, 40–48.
Gameiro, S. R., Caballero, J. A., Higgins,
J. P., Apelian, D., and Hodge, J. W.
(2011). Exploitation of differential
homeostatic proliferation of T-cell
www.frontiersin.org May 2012 | Volume 2 | Article 43 | 5
Slovin Vaccines and chemotherapy combinations – does 1+1=2?
subsets following chemotherapy
to enhance the efﬁcacy of vaccine-
mediated antitumor responses
Cancer Immunol. Immunother. 60,
1227–1242.
Garnett, C. T., Schlom, J., and Hodge,
J. W. (2008). Combination of doc-
etaxel and recombinant vaccine
enhances T-cell responses and anti-
tumor activity: effects of docetaxel
on immune enhancement. Clin.
Cancer Res. 14, 3536–3544.
Gerritsen,W.,vandenEertwegh,A. J.,de
Gruijl,T.,Giaccone,G.,Scheper,R. J.,
Lowy, I.,Levy,E.,Hege,K., and Sacks,
N. (2008). Expanded phase I combi-
nation trial of GVAX immunother-
apy for prostate cancer and ipili-
mumab in patients with metastatic
hormone-refractory prostate cancer
(mHPRC). J. Clin. Oncol. 26, abstr.
5146.
Grinshtein, N.,Ventresca,M.,Margl, R.,
Bernard, D., Yang, T. C., Millar, J.
B., Hummel, J., Beermann, F., Wan,
Y., and Bramson, J. L. (2009). High-
dose chemotherapy augments the
efﬁcacy of recombinant adenovirus
vaccines and improves the therapeu-
tic outcome. Cancer Gene Ther. 16,
338–350.
Grivennikov, S. I., Greten, F. R.,
and Karin, M. (2010). Immunity,
inﬂammation, and cancer. Cell 140,
883–899.
Halabi, S., Small, E. J., Kantoff, P.
W., Kattan, M. W., Kaplan, E. B.,
Dawson, N. A., Levine, E. G., Blu-
menstein, B. A., and Vogelzang,
N. J. (2003). Prognostic model
for predicting survival in men
with hormone-refractory metastatic
prostate cancer J. Clin. Oncol. 21,
1232–1237.
Higano,D., Saad, F., Somer, B., Curti, B.,
Petrylak, D., Drake, C. G., Schnell,
F., Redfern, C. H., Schrijvers, D., and
Sacks, N. (2009). “A phase III trial of
GVAX immunotherapy for porstate
cancer versus docetaxel plus pred-
nisone in asymptomatic, castration-
resistant prostate cancer (CRPC),”
in 2009 Genitourinary Cancers Sym-
posium, Abstract LBA150, Orlando,
FL.
Hodi, F. S., Butler, M., Oble, D. A., Sei-
den, M. V., Haluska, F. G., Kruse,
A.,MacRae, S., Nelson,M., Canning,
C., Lowy, I., Korman, A., Lautz, D.,
Russell, S., Jaklitsch, M. T., Ramaiya,
N., Chen, T. C., Neuberg, D., Alli-
son, J. P., Mihm, M. C., and Dranoff,
G. (2008). Immunologic and clinical
effects of antibody blockade of cyto-
toxic T lymphocyte-associated anti-
gen 4 inpreviously vaccinated cancer
patients. Proc. Natl. Acad. Sci. U.S.A.
105, 3005–3010.
Hodi, F. S., O’Day, S. J., McDermott,
D. F., Weber, R. W., Sosman, J. A.,
Haanen, J. B., Gonzalez, R., Robert,
C., Schadendorf, D., Hassel, J. C.,
Akerley, W., van den Eertwegh, A. J.,
Lutzky, J., Lorigan, P., Vaubel, J. M.,
Linette, G. P.,Hogg,D.,Ottensmeier,
C. H., Lebbé, C., Peschel, C., Quirt,
I., Clark, J. I., Wolchok, J. D., Weber,
J. S., Tian, J., Yellin, M. J., Nichol,
G. M., Hoos, A., and Urba, W. J.
(2010). Improved survival with ipil-
imumab in patients with metasta-
tic melanoma. N. Engl. J. Med. 363,
711–723.
Hoos,A., Eggermont,A. M., Janetzki, S.,
Hodi, F. S., Ibrahim, R., Anderson,
A., Humphrey, R., Blumenstein, B.,
Old, L., and Wolchok, J. (2010).
Improved endpoints for cancer
immunotherapy trials. J. Natl. Can-
cer Inst. 102, 1388–1397.
Hoos, A., Parmiani, G., Hege, K., Sznol,
M., Loibner, H., Eggermont, A.,
Urba,W., Blumenstein, B., Sacks, N.,
Keilholz, U., Nichol, G., and Can-
cer Vaccine Clinical Trial Working
Group. (2007). A clinical develop-
ment paradigm for cancer vaccines
and related biologics. J. Immunother.
30, 1–15.
Javeed, A., Ashraf,M., Riaz, A., Ghafoor,
A., Afzal, S., and Mukhtar, M. M.
(2009). Paclitaxel and immune sys-
tem. Eur. J. Pharm. Sci. 38, 283–290.
Kantoff, P. W., Higano, C. S., Shore, N.
D., Berger, E. R., Small, E. J., Pen-
son, D. F., Redfern, C. H., Ferrari,
A. C., Dreicer, R., Sims, R. B., Xu,
Y., Frohlich,M.W., Schellhammer, P.
F., and IMPACT Study Investigators.
(2010). Sipuleucel-T immunother-
apy for castration-resistant prostate
cancer. N. Engl. J. Med. 363,
411–422.
Kodumudi, K. N., Woan, K., Gilvary,
D. L., Sahakian, E., Wei, S., and
Djeu, J. Y. (2010). A novel chemoim-
munomodulating property of doc-
etaxel: suppression of myeloid-
derived suppressor cells in tumor
bearers. Clin. Cancer Res. 16,
4583–4594.
Li, N., Qin, H., Li, X., Zhou, C., Wang,
D., Ma, W., Lin, C., Zhang, Y., Wang,
S., and Zhang, S. (2007). Synergis-
tic antitumor effect of chemotactic-
prostate tumor-associated antigen
gene-modiﬁed tumor cell vaccine
and anti-CTLA-4 mAb in murine
tumor model. Immunol. Lett. 113,
90–98.
Ma,Y., Conforti, R.,Aymeric, L., Locher,
C., Kepp, O., Kroemer, G. C. J.,
DeMarzo, A. M., Meeker, A. K.,
Isaacs,W. B.,Drake,C.G., andZitvo-
gel, L. (2011). How to improve the
immunogenicity of chemotherapy
and radiotherapy. Cancer Metastasis
Rev. 30, 71–82.
Madan, R. A., Mohebtash, M., Arlen,
P. M., Rauckhorst, M., Ferrara, T.
A., Steinberg, S. M., Dahut, W. L.,
Schlom, J., and Gulley, J. L. (2010a).
Overall survival (OS) analysis of a
phase l trial of a vector-based vaccine
(PSA-TRICOM) and ipilimumab
(Ipi) in the treatment of metastatic
castration-resistant prostate cancer
(mCRPC). J. Clin. Oncol. 28, abstr.
2550.
Madan, R. A., Gulley, J. L., Fojo, T., and
Dahut, W. L. (2010b). Therapeutic
cancer vaccines in prostate cancer:
the paradox of improved survival
without changes in time to progres-
sion. Oncologist 15, 969–975.
McDonnell, A. M., Nowak, A. K.,
and Lake, R. A. (2011). Contribu-
tion of the immune system to the
chemotherapeutic response. Semin.
Immunopathol. 33, 353–367.
Mlecnik, B., Bindea, G., Pages, F., and
Galon, J. (2011). Tumor immuno-
surveillance in human cancers. Can-
cer Metastasis Rev. 30, 5–12.
Mohebtash, M., Madan, R. A., Arlen,
P. M., Rauckhorst, M., Tsang, K. Y.,
Cereda, V., Vergati, M., Poole, D. J.,
Dahut, W. L., Schlom, J., Gulley, J.
L., and National Cancer Institute,
Bethesda,MD (2009). Phase I trial of
targeted therapywithPSA-TRICOM
vaccine (V) and ipilimumab (ipi)
in patients (pts) with metastatic
castration-resistant prostate cancer
(mCRPC). J. Clin. Oncol. 27, abstr.
5144.
Noguchi,M., Itoh,K., Suekane,S.,Mori-
naga, A., Sukehiro, A., Suetsugu, N.,
Katagiri, K., Yamada, A., and Noda,
S. (2004). Immunological monitor-
ing during combination of patient-
oriented peptide vaccination and
estramustine phosphate in patients
with metastatic hormone refractory
prostate cancer. Prostate 60, 32–45.
Noguchi, M., Uemura, H., Naito, S.,
Akaza, H., Yamada, A., and Itoh,
K. (2011). A phase I study of per-
sonalized peptide vaccination using
14 kinds of vaccine in combina-
tion with low-dose estramustine
in HLA-A24-positive patients with
castration-resistant prostate cancer.
Prostate 71, 470–479.
Pagès, F., Galon, J., and Fridman, W.
H. (2008). The essential role of the
in situ immune reaction in human
colorectal cancer. J. Leukoc. Biol. 84,
981–987.
Petrylak, D. (2011). “Deﬁning the
optimal role of immunother-
apy and chemotherapy,” in
Chemotherapy Foundation Sym-
posium XXIV2006. Available at:
http://www.mssmtv.org/player/
player.php?id=111006ada_petrylak.
[accessed August 24].
Petrylak, D. P., Schellhammer, P.
F., Small, E., and Frohlich, M.
W. (2007). “Androgen independent
prostate cancer (AIPC) patients
who receive sipuleucel-T followed
by docetaxel have prolonged sur-
vival,” in American Urology Associa-
tion Meeting Abstracts, Orlando, FL,
605.
Poschke, I., Mougiakakos, D., and
Kiessling, R. (2011). Camouﬂage
and sabotage: tumor escape from the
immune system. Cancer Immunol.
Immunother. 60, 1161–1171.
Ramakrishnan, R., Assudani, D.,
Nagaraj, S., Hunter, T., Cho, H.
I., Antonia, S., Altiok, S., Celis,
E., and Gabrilovich, D. I. (2010).
Chemotherapy enhances tumor
cell susceptibility to CTL-mediated
killing during cancer immunother-
apy in mice. J. Clin. Invest. 120,
1111–1124.
Rini, B. I., Weinber, V., Fong, L., Conry,
S., Hershberg, R. M., and Small, E. J.
(2006). Combination immunother-
apy with prostatic acid phos-
phatase pulsed antigen-presenting
cells (Provenge) plus bevacizumab
in patients with serologic progres-
sion of prostate cancer after deﬁni-
tive local therapy.Cancer 107,68–74.
Saha, A., and Chatterjee, S. K. (2010).
Combination of CTL-associated
antigen-4 blockade and depletion
of CD25 regulatory T cells enhance
tumour immunity of dendritic cell-
based vaccine in a mouse model of
colon cancer. Scand. J. Immunol. 71,
70–82.
Sarnaik, A. A., Yu, B., Yu, D., Morelli,
D., Hall, M., Bogle, D., Yan, L.,
Targan, S., Solomon, J., Nichol, G.,
Yellin, M., and Weber, J. S. (2011).
Extended dose ipilimumab with a
peptide vaccine: immune correlates
associated with clinical beneﬁt in
patientswith resectedhigh-risk stage
IIIc/IV melanoma. Clin. Cancer Res.
17, 896–906.
Sfanos, K. S., Bruno, T. C., Maris, C.
H., Xu, L., Thoburn, C. J., DeMarzo,
A. M., Meeker, A. K., Isaacs, W. B.,
and Drake, C. G. (2008). Pheno-
typic analysis of prostate-inﬁltrating
lymphocytes reveals TH17 and Treg
skewing. Clin. Cancer Res. 14,
3254–3261.
Sistigu, A., Viaud, S., Chaput, N.,
Bracci, L., Proietti, E., and Zitvo-
gel, L. (2011). Immunomodula-
tory effects of cyclophosphamide
and implementations for vaccine
design. Semin. Immunopathol. 33,
369–383.
Frontiers in Oncology | Genitourinary Oncology May 2012 | Volume 2 | Article 43 | 6
Slovin Vaccines and chemotherapy combinations – does 1+1=2?
Slovin, S. F. (2008). Tribulations
or triumphs in prostate cancer
immunotherpy: on the road to vic-
tory? Expert Rev. Anticancer Ther. 8,
465–474.
Small, E., Demkow, T., Gerritsen, W.
R., Rolland, F., Hoskin, P., Smith, D.
C., Parker, C., Chondros, D., Ma, J.,
and Hege, K. (2009). “A phase III
trial of GVAX immunotherapy for
prostate cancer in combination with
docetaxel versus docetaxel plus pred-
nisone in symptomatic, castration-
resistant prostate cancer (CRPC),” in
2009 Genitourinary Cancers Sympo-
sium, Orlando, Abstract LBA150.
Vesely,M. D., Kershaw,M. H., Schreiber,
R. D., and Smyth, M. J. (2011).
Natural innate and adaptive immu-
nity to cancer. Annu. Rev. Immunol.
29, 235–271.
Vicari,A. P., Luu, R., Zhang,N., Patel, S.,
Makinen, S. R.,Hanson,D. C.,Weer-
atna, R. D., and Krieg, A. M. (2009).
Paclitaxel reduces regulatory T cell
numbers and inhibitory function
and enhances the anti-tumor effects
of the TLR9 agonist PF-3512676
in the mouse. Cancer Immunol.
Immunother. 58, 615–628.
Wada, S., Yoshimura, K., Hipkiss, E.
L., Harris, T. J., Yen, H. R., Gold-
berg, M. V., Grosso, J. F., Getnet, D.,
Demarzo,A. M.,Netto, G. J., Anders,
R., Pardoll, D. M., and Drake, C.
G. (2009). Cyclophosphamide aug-
ments antitumor immunity: stud-
ies in an autochthonous prostate
cancer model. Cancer Res. 69,
4309–4318.
Wolchok, J. D., Hoos, A., O’Day, S.,
Weber, J. S., Hamid, O., Lebb,
C., Maio, M., Binder, M., Bohn-
sack, O., Nichol, G., Humphrey,
R., and Hodi, F. S. (2009).
Guidelines for the evaluation
of immune therapy activity in solid
tumors: immune-related response
criteria. Clin. Cancer Res. 15,
7412–7420.
Wu, Y., and Zhou, B. P. (2009).
Inﬂammation: a driving force speeds
cancer metastasis. Cell Cycle 8,
3267–3273.
Yuan, J., Gnjatic, S., Li, H., Powel,
S., Gallardo, H. F., Ritter, E., Ku,
G. Y., Jungbluth, A. A., Segal, N.
H., Rasalan, T. S., Manukian, G.,
Xu, Y., Roman, R. A., Terzulli,
S. L., Heywood, M., Pogoriler,
E., Ritter, G., Old, L. J., Allison,
J. P., and Wolchok, J. D. (2008).
CTLA-4 blockade enhances poly-
functional NY-ESO-1 speciﬁc T cell
responses in metastatic melanoma
patients with clinical beneﬁt.
Proc. Natl. Acad. Sci. U.S.A. 105,
20410–20415.
Zitvogel, L., Apetoh, L., Ghiringhelli, F.,
Andre, F., Tesniere, A., and Kroemer,
G. (2008). The anticancer immune
response: indispensable for thera-
peutic success? J. Clin. Invest. 118,
1991–2001.
Conﬂict of Interest Statement: The
author declares that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 10 January 2012; paper pending
published: 03 February 2012; accepted:
12 April 2012; published online: 30 May
2012.
Citation: Slovin SR (2012) Toward max-
imizing immunotherapy in metastatic
castration-resistant prostate cancer –
rationale for combinatorial approaches
using chemotherapy. Front. Oncol. 2:43.
doi: 10.3389/fonc.2012.00043
This article was submitted to Frontiers
in Genitourinary Oncology, a specialty of
Frontiers in Oncology.
Copyright © 2012 Slovin. This is an
open-access article distributed under the
terms of the Creative Commons Attribu-
tion Non Commercial License, which per-
mits non-commercial use, distribution,
and reproduction in other forums, pro-
vided the original authors and source are
credited.
www.frontiersin.org May 2012 | Volume 2 | Article 43 | 7
